 Home > Biochemistry News > Biotechnology News > Potential new therapy for dangerous middle-aged and elderly blood cancer

Potential new therapy for dangerous middle-aged and elderly blood cancer

 Last Update: 2021-08-28
 Source: Internet
 Author: User

Tags

cancer cell growth

prostate cancer biomarkers

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The drug called palbociclib may be able to prevent bone marrow scars that cannot be prevented by existing myelofibrosis treatments

"Current treatment methods can only relieve symptoms and cannot significantly improve myelofibrosis

Myelofibrosis: a dangerous cancer

Myelofibrosis is a type of leukemia

Existing treatment methods for bone marrow fibrosis cannot solve the characteristics of bone marrow scars

In two different mouse models of myelofibrosis, Palbociclib itself can reduce bone marrow scars

Combining the drug with Ruxolitinib will bring more benefits, restore bone marrow and white blood cell counts to normal levels, and significantly reduce the enlarged spleen of mice

More research is needed to determine whether these findings apply to human patients

"Combined treatments including palbociclib and ruxolitinib will be able to reduce the dose of each inhibitor, thereby reducing toxicity while improving efficacy," they wrote in a new scientific paper outlining their findings

Researchers pointed out that because ruxolitinib treatment cannot significantly reduce myelofibrosis, and long-term use often loses efficacy, new myelofibrosis treatment methods are particularly needed

Mohi said: "The findings of this study are very exciting.

Avik Dutta, Dipmoy Nath, Yue Yang, Bao T.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.